MX362955B - Vacuna de lipopolisacaridos. - Google Patents

Vacuna de lipopolisacaridos.

Info

Publication number
MX362955B
MX362955B MX2014011305A MX2014011305A MX362955B MX 362955 B MX362955 B MX 362955B MX 2014011305 A MX2014011305 A MX 2014011305A MX 2014011305 A MX2014011305 A MX 2014011305A MX 362955 B MX362955 B MX 362955B
Authority
MX
Mexico
Prior art keywords
vaccine
antigen
gram
whole cell
negative bacterium
Prior art date
Application number
MX2014011305A
Other languages
English (en)
Spanish (es)
Other versions
MX2014011305A (es
Inventor
Ryuichi Sakamoto
Masashi Sakaguchi
Original Assignee
The Chemo Sero Therapeutic Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Chemo Sero Therapeutic Res Institute filed Critical The Chemo Sero Therapeutic Res Institute
Publication of MX2014011305A publication Critical patent/MX2014011305A/es
Publication of MX362955B publication Critical patent/MX362955B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2014011305A 2012-03-22 2013-02-19 Vacuna de lipopolisacaridos. MX362955B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012065162 2012-03-22
PCT/JP2013/054038 WO2013140919A1 (ja) 2012-03-22 2013-02-19 Lpsワクチン

Publications (2)

Publication Number Publication Date
MX2014011305A MX2014011305A (es) 2014-10-17
MX362955B true MX362955B (es) 2019-02-26

Family

ID=49222384

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011305A MX362955B (es) 2012-03-22 2013-02-19 Vacuna de lipopolisacaridos.

Country Status (9)

Country Link
US (3) US9345756B2 (cg-RX-API-DMAC7.html)
EP (1) EP2829281B1 (cg-RX-API-DMAC7.html)
JP (1) JP6088489B2 (cg-RX-API-DMAC7.html)
CN (1) CN104244972A (cg-RX-API-DMAC7.html)
BR (1) BR112014021959B1 (cg-RX-API-DMAC7.html)
ES (1) ES2708430T3 (cg-RX-API-DMAC7.html)
MX (1) MX362955B (cg-RX-API-DMAC7.html)
RU (1) RU2637448C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013140919A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104244972A (zh) * 2012-03-22 2014-12-24 一般财团法人化学及血清疗法研究所 Lps疫苗
KR20160061989A (ko) * 2013-10-03 2016-06-01 닛토덴코 가부시키가이샤 코점막 백신 조성물
CN106177937A (zh) * 2016-07-25 2016-12-07 江苏省农业科学院 鸡减蛋综合征和禽脑脊髓炎二联灭活疫苗及其制备方法
CN109486741B (zh) * 2018-12-20 2021-10-29 天津瑞普生物技术股份有限公司 一种副鸡禽杆菌的灭活方法
CN114746113B (zh) * 2019-11-29 2025-11-14 勃林格殷格翰动物保健有限公司 针对副鸡禽杆菌和禽脑脊髓炎病毒和禽痘病毒的三联疫苗
EP4171623A4 (en) * 2020-06-26 2024-08-14 Zivo Bioscience, Inc. Positive latency effects on coccidiosis prevention and treatment via animal feed
US20220053799A1 (en) * 2020-06-26 2022-02-24 Zivo Bioscience, Inc. Positive latency effects on coccidiosis prevention and treatment via animal feed
CN116033923A (zh) * 2020-08-12 2023-04-28 齐沃生物科学股份有限公司 Variovorax病菌作为球虫病替代治疗的用途
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
WO2025260072A1 (en) * 2024-06-14 2025-12-18 Zivo Bioscience, Inc. Gram-negative bacteria for use in the prevention and treatment of disease in poultry
WO2026043873A1 (en) * 2024-08-19 2026-02-26 Elanco Us Inc. Inactivated salmonella vaccine formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713073B1 (en) * 1998-07-24 2004-03-30 Megan Health, Inc. Method of vaccination of newly hatched poultry
JP4456698B2 (ja) 1999-07-16 2010-04-28 生化学工業株式会社 エンドトキシンショック抑制剤
WO2004052394A1 (en) 2002-12-06 2004-06-24 Biosynth S.R.L. Broad-spectrum lps based vaccines of unencapsulated strains of haemophilus influenzae and other pathogenic species of gram-negative bacteria
EP1747262B1 (en) * 2004-05-14 2012-09-26 National Research Council Of Canada Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
US20050260225A1 (en) * 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
US8465755B2 (en) * 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
RU2377015C1 (ru) * 2008-04-29 2009-12-27 Николай Васильевич Пименов Вакцина инактивированная против сальмонеллеза голубей и способ ее применения
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
CN104244972A (zh) * 2012-03-22 2014-12-24 一般财团法人化学及血清疗法研究所 Lps疫苗

Also Published As

Publication number Publication date
JP6088489B2 (ja) 2017-03-01
CN104244972A (zh) 2014-12-24
US20170281745A1 (en) 2017-10-05
JPWO2013140919A1 (ja) 2015-08-03
BR112014021959B1 (pt) 2022-12-06
US9345756B2 (en) 2016-05-24
US20150086590A1 (en) 2015-03-26
ES2708430T3 (es) 2019-04-09
EP2829281B1 (en) 2019-01-16
EP2829281A4 (en) 2015-11-11
BR112014021959A8 (pt) 2022-10-18
BR112014021959A2 (cg-RX-API-DMAC7.html) 2017-06-20
RU2637448C2 (ru) 2017-12-04
EP2829281A1 (en) 2015-01-28
MX2014011305A (es) 2014-10-17
US20160228526A1 (en) 2016-08-11
WO2013140919A1 (ja) 2013-09-26
RU2014138021A (ru) 2016-05-20
US10279025B2 (en) 2019-05-07

Similar Documents

Publication Publication Date Title
BR112014021959A8 (pt) Composição de vacina de salmonella para aves
MX2020011696A (es) Formulacion arn para inmunoterapia.
EP4303229A3 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
EA201300915A1 (ru) Новый европейский штамм prrsv
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
PH12013502442A1 (en) Inactivated dengue virus vaccine
MX363307B (es) Plataformas para suministro de antigenos.
MX363529B (es) Vesículas de membrana externa.
MX2015008027A (es) Proceso de glicoconjugacion.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
GB2518813A (en) OMV vaccine against Burkholderia infections
EA201500701A1 (ru) Способ создания вакцины против микоплазм
MX373361B (es) Composiciones inmunológicas que contienen histophilus somni atenuado.
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MX373395B (es) Vacuna de haemophilus parasuis para serovar tipo cuatro.
MX357538B (es) Vacunas para meningococo de serogrupo x.
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
GB201017519D0 (en) Vaccines
UA110822C2 (uk) Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів

Legal Events

Date Code Title Description
FG Grant or registration